<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829983</url>
  </required_header>
  <id_info>
    <org_study_id>NMRBA</org_study_id>
    <nct_id>NCT02829983</nct_id>
  </id_info>
  <brief_title>Clarithromycin as Adjuvant to Periodontal Debridement</brief_title>
  <official_title>Clarithromycin as Adjuvant to Periodontal Debridement in the Treatment of Generalized Aggressive Periodontitis: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Estadual Paulista Júlio de Mesquita Filho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Estadual Paulista Júlio de Mesquita Filho</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the periodontal clinical response and the possible adverse effects of the
      clarithromycin combined to periodontal mechanical therapy in the treatment of patients with
      generalized aggressive periodontitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the periodontal clinical response and the possible adverse effects of the
      clarithromycin combined to periodontal mechanical therapy in the treatment of patients with
      generalized aggressive periodontitis.Forty patients were select and randomly assigned into
      two groups: Group clarithromycin with 20 subjects that received one-stage full-mouth
      ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3
      days; group placebo with 20 subjects that received FMUD associated with placebo. Probing
      depth (PD), gain in clinical attachment level (CAL) and bleeding on probing (BOP) were
      evaluated at baseline, 3 and 6 months post- operatively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Attachment Level</measure>
    <time_frame>6 months</time_frame>
    <description>Distance from bottom of pocket to the cement-enamel junction (CEJ).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probing Depth</measure>
    <time_frame>6 months</time_frame>
    <description>Distance from the bottom of sulcus/pocket to gingival margin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Aggressive Periodontitis</condition>
  <arm_group>
    <arm_group_label>clarithromycin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Use of 500mg of Clarithromycin twice a day for 3 days</description>
    <arm_group_label>clarithromycin group</arm_group_label>
    <other_name>macrolide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Use of placebo tablets twice a day for 3 days.</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>One-stage full-mouth ultrasonic debridement (FMUD)</intervention_name>
    <description>One session of Periodontal debridement using ultrasonic device.</description>
    <arm_group_label>clarithromycin group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of Generalized Aggressive Periodontitis

          -  presence of ≥20 teeth

          -  presence of ≥ 6 sites presenting probing depth (PD) ≥5mm with bleeding on probing
             (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to
             two other non-contiguous teeth between them)

          -  good general health

          -  &lt;35 years of age

          -  agree to participate in the study and sign a written consent

        Exclusion Criteria:

          -  pregnant or lactating

          -  suffering from any other systemic disease (e.g. cardiovascular, diabetes, blood
             dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease

          -  received antimicrobials in the previous 6 months

          -  taking long-term anti-inflammatory drugs

          -  received a course of periodontal treatment within the last 12 months

          -  smoked
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro P Santamaria, DDS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UPECLIN HC FM Botucatu Unesp</affiliation>
  </overall_official>
  <results_reference>
    <citation>Casarin RC, Peloso Ribeiro ED, Sallum EA, Nociti FH Jr, Gonçalves RB, Casati MZ. The combination of amoxicillin and metronidazole improves clinical and microbiologic results of one-stage, full-mouth, ultrasonic debridement in aggressive periodontitis treatment. J Periodontol. 2012 Aug;83(8):988-98. doi: 10.1902/jop.2012.110513. Epub 2012 Jan 30.</citation>
    <PMID>22288485</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <results_first_submitted>May 9, 2017</results_first_submitted>
  <results_first_submitted_qc>October 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2017</results_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</investigator_affiliation>
    <investigator_full_name>Mauro Pedrine Santamaria</investigator_full_name>
    <investigator_title>DDS,MS,PhD</investigator_title>
  </responsible_party>
  <keyword>clarithromycin</keyword>
  <keyword>periodontal debridement</keyword>
  <keyword>aggressive periodontitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Aggressive Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clarithromycin Group</title>
          <description>20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg – 12/12 hours) for 3 days.
Clarithromycin: Use of 500mg of Clarithromycin twice a day for 3 days
One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
Placebo: Use of placebo tablets twice a day for 3 days.
One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clarithromycin Group</title>
          <description>20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg – 12/12 hours) for 3 days.
Clarithromycin: Use of 500mg of Clarithromycin twice a day for 3 days
One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
Placebo: Use of placebo tablets twice a day for 3 days.
One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" spread="3.7"/>
                    <measurement group_id="B2" value="31.25" spread="4.6"/>
                    <measurement group_id="B3" value="31.32" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Probing depht</title>
          <units>milimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.34" spread="0.56"/>
                    <measurement group_id="B2" value="3.53" spread="0.6"/>
                    <measurement group_id="B3" value="3.43" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>clinical attachment level</title>
          <units>milimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.48" spread="0.66"/>
                    <measurement group_id="B2" value="3.63" spread="0.7"/>
                    <measurement group_id="B3" value="3.55" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>bleeding on probing</title>
          <units>percentage of sites</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="19"/>
                    <measurement group_id="B2" value="54" spread="30"/>
                    <measurement group_id="B3" value="53.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>gingival recession</title>
          <units>milimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.14" spread="0.16"/>
                    <measurement group_id="B2" value="0.1" spread="0.12"/>
                    <measurement group_id="B3" value="0.12" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>plaque index</title>
          <description>Plaque index is the relation between the sites with deposits of plaque and the sites of full mouth divided for 100.</description>
          <units>percentage of sites</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="23"/>
                    <measurement group_id="B2" value="62" spread="25"/>
                    <measurement group_id="B3" value="60.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Attachment Level</title>
        <description>Distance from bottom of pocket to the cement-enamel junction (CEJ).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clarithromycin Group</title>
            <description>20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg – 12/12 hours) for 3 days.
Clarithromycin: Use of 500mg of Clarithromycin twice a day for 3 days
One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
Placebo: Use of placebo tablets twice a day for 3 days.
One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Attachment Level</title>
          <description>Distance from bottom of pocket to the cement-enamel junction (CEJ).</description>
          <units>milimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="0.35"/>
                    <measurement group_id="O2" value="3.03" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probing Depth</title>
        <description>Distance from the bottom of sulcus/pocket to gingival margin</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clarithromycin Group</title>
            <description>20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg – 12/12 hours) for 3 days.
Clarithromycin: Use of 500mg of Clarithromycin twice a day for 3 days
One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
Placebo: Use of placebo tablets twice a day for 3 days.
One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.</description>
          </group>
        </group_list>
        <measure>
          <title>Probing Depth</title>
          <description>Distance from the bottom of sulcus/pocket to gingival margin</description>
          <units>milimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="0.3"/>
                    <measurement group_id="O2" value="2.86" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week after periodontal treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clarithromycin Group</title>
          <description>20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg – 12/12 hours) for 3 days.
Clarithromycin: Use of 500mg of Clarithromycin twice a day for 3 days
One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
Placebo: Use of placebo tablets twice a day for 3 days.
One-stage full-mouth ultrasonic debridement (FMUD): One session of Periodontal debridement using ultrasonic device.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mauro Pedrine Santamaria</name_or_title>
      <organization>Universidade Estadual Paulista Júlio de Mesquita Filho</organization>
      <phone>3947-9033</phone>
      <email>mauro.santamaria@ict.unesp.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

